Gentherm Incorporated

What they do

Gentherm operates in two reportable segments: Automotive and Medical. Automotive designs, develops, manufactures and sells Climate Control Seats, Climate Control Interiors, Lumbar and Massage Comfort Solutions, Valve Systems, and Climate and Comfort Electronics, with production located near major OEM customers. Medical provides patient temperature management systems for hyper-hypothermia therapy in intensive care, normothermia in surgical procedures, and other warming/cooling therapies used in hospitals worldwide.

Revenue drivers

• Automotive Climate and Comfort Solutions — Largest revenue driver, including Climate Control Seats, Climate Control Interiors, Lumbar and Massage, and Climate and Comfort Electronics; in Q1 2026 this line grew 13.6% year over year, or 9.8% ex-FX, outperforming the relevant light vehicle production market by 14 percentage points.
• Valve Systems and other automotive products — Automotive segment product line supplying valve systems and other components; grouped within the Automotive reportable segment, which accounted for the majority of total product revenues.
• Medical patient temperature management — Medical segment sells patient temperature management systems to hospitals globally; in Q1 2026 Medical product revenues declined 6.3% year over year on a constant-currency basis.

Recent performance

In Q1 2026, Gentherm reported product revenues of $393.7 million, up 11.3% year over year and up 7.2% excluding foreign currency translation. Automotive revenue rose while Medical declined; Automotive Climate and Comfort Solutions grew 13.6% year over year. Gross margin improved to 24.7% from 24.4%, net income was $4.2 million versus a $(0.1) million loss a year earlier, and adjusted EBITDA rose to $49.3 million (12.5% of revenue) from $39.3 million (11.1%). GAAP diluted EPS was $0.14 and adjusted diluted EPS was $0.84; cash flow from operations was negative $(5.0) million.

Strategy

Management is executing a strategic plan focused on establishing a more robust operating system, organic growth initiatives in home, office and medical markets, and manufacturing footprint optimization. The company announced a Reverse Morris Trust transaction with Modine Manufacturing to combine Modine's Performance Technologies business with Gentherm, which it describes as creating a stronger enterprise with an expanded product portfolio and broader end-market exposure. Recent commercial actions include first deliveries of home and office solutions to KUKA Home in Asia and submission of a 510(k) premarket notification to the FDA for the ThermAffyx Patient Safety System. Automotive new business awards totaled $395 million in Q1 2026. The Modine transaction is subject to shareholder and regulatory approvals and is targeted to close by year-end 2026.

Risks

• Modine transaction closing risk — The Reverse Morris Trust combination with Modine Performance Technologies requires shareholder approvals, financing completion for SpinCo, a customary IRS tax ruling, and regulatory approvals, any of which may delay or prevent closing.
• Light vehicle production sensitivity — Automotive sales depend on light vehicle production by OEMs in North America, Europe, China, Japan and South Korea, and guidance assumes a low single-digit production decline in relevant markets for full year 2026 versus 2025.
• Automotive price and cost pressure — Gross margin improvement in Q1 2026 was partially offset by annual price reductions and higher labor costs, indicating persistent pricing and cost headwinds.
• Tariff and trade uncertainty — 2026 guidance is based on tariffs in effect as of April 2026, and changes in tariff policy could affect costs and results.

Outlook

Management left full-year 2026 guidance unchanged: product revenues of $1.5 billion to $1.6 billion, adjusted EBITDA of $175 million to $195 million, and adjusted free cash flow of $80 million to $100 million. Guidance assumes tariffs in effect as of April 2026, light vehicle production in relevant markets declining at a low single-digit rate, and a EUR to USD exchange rate of $1.16/Euro, with an effective tax rate of approximately 30%. It does not reflect any impact from the planned Modine Performance Technologies combination. Management states the Modine transaction remains on track to close by the end of 2026.